Status:
COMPLETED
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
Brief Summary
This study aims to investigate the expression of Melanoma-associated antigen 3 (MAGE-A3), Melanoma-associated antigen C2 (MAGE-C2), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), L antigen ...
Detailed Description
This study will be based upon the analysis of samples and patient-related data already available at the various investigation sites. There will be no study treatment and no study-specific procedure ca...
Eligibility Criteria
Inclusion
- For inclusion of a tissue sample, all of the following criteria must be met:
- The patient had pathologically proven stage I, II or III NSCLC.
- All the data required are available from patient's records.
- Many patients may no longer be alive, or no longer be in contact with the investigation sites. Thus, patients will not be required to give their informed consent before inclusion in the study.
Exclusion
- Not applicable
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
377 Patients enrolled
Trial Details
Trial ID
NCT01837511
Start Date
August 1 2007
End Date
January 1 2008
Last Update
April 23 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Singapore, Singapore, 169608
2
GSK Investigational Site
Seoul, South Korea, 137-701
3
GSK Investigational Site
Songpa-gu, Seoul, South Korea, 138-736